Prof Linn presents data at the 2016 San Antonio Breast Cancer Symposium from the TEAM IIb trial, in which post-menopausal women with hormone receptor positive breast cancer, with no metastases, were treated with 3 years of adjuvant bisphosphonate therapy.

She describes no proof of statisically significant benefit of 3 years of ibandronate, with a slight increase in gastrointestinal side effects, and non-significant trend towards improved disease free survival and reduced bone metastases.